EUCTR2011-002749-37-ES进行中（未招募）1 期
Validation of digital-PCR analysis through programmed imatinib interruption in PCR negative chronic myeloid leukemia patients.
niveristy of Milano-Bicocca0 个研究点目标入组 100 人开始时间: 2011年12月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signed and dated IRB/IEC-approved Informed Consent. 2. Age >/= 18 years. 3. Male or female patients with CML diagnosed in chronic phase and who have been treated for more than 2 consecutive years with imatinib therapy. 4. Sustained Complete Molecular Response (as defined by the treating center) for at least 18 months with imatinib treatment. 5. A minimum of 3 CMR determined by Q-RT-PCR analysis to support disease status, with the least one performed within 3 calendar months prior to enrollment date. 6. Willingness and ability to comply with scheduled visits, laboratory tests and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1. Allogenic hematopoietic stem cell transplantation. 2. Known active infections, including human immunodeficiency virus (HIV) positivity. 3. Current enrollment in another clinical trial. 4. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results.
研究者
相似试验
进行中（未招募）
1 期
Validation of a new analytical method in asymptomatic chronic myeloid leukemia patients for whom the treatment with imatinib is suspended.Chronic Myeloid Leukemia (CML) with substained Complete Molecular Response (CMR).MedDRA version: 14.1 Level: LLT Classification code 10052065 Term: Chronic phase chronic myeloid leukaemia System Organ Class: 100000004864EUCTR2011-002749-37-DEniveristy of Milano-Bicocca100
进行中（未招募）
不适用
Validation of a new analytical method in asymptomatic chronic myeloid leukemia patients for whom the treatment with imatinib is suspended.EUCTR2011-002749-37-NLniveristy of Milano-Bicocca100
进行中（未招募）
1 期
Validation of a new analytical method in asymptomatic chronic myeloid leukemia patients for whom the treatment with imatinib is suspended.Chronic Myeloid Leukemia (CML) with substained Complete Molecular Response (CMR).MedDRA version: 14.1Level: LLTClassification code 10052065Term: Chronic phase chronic myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002749-37-ITIVERSITA' DEGLI STUDI DI MILANO - BICOCCA100
已完成
4 期
Validation of digital-PCR analysis through programmed imatinib interruption in PCR negative chronic myeloid leukemia patients.Chronic Myeloid Leukemia (CML) with sustained Complete Molecular Response (CMR) / Chronic Myeloid Leukemia (CML) asymptomatic and with no sign of disease by the most sensitive conventional hospital investigations.10024324NL-OMON37795niversity of Milano-Bicocca5
已完成
4 期
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML PatientsChronic Myeloid LeukemiaNCT01578213University of Milano Bicocca112